We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Immunomedics Gets CRL From FDA for Breast Cancer Candidate
Read MoreHide Full Article
Immunomedics, Inc., suffered a setback when the company received a Complete Response Letter (CRL) from the FDA with regard to the Biologics License Application (BLA) for its lead candidate sacituzumab govitecan.
The BLA is seeking an accelerated approval of sacituzumab govitecan for treating patients with metastatic triple-negative breast cancer (mTNBC), who have received at least two prior therapies for metastatic disease.
The issues related to the CRL primarily focused on Chemistry, Manufacturing and Control matters and hence, the company is not required to generate any new clinical or preclinical data.
The company plans to work with the FDA to solve this issue. Last July, the FDA notified the company that the BLA has been accepted and the agency granted Priority Review with a target action date of Jan 18, 2019.
The news comes as a disappointment for this clinical-stage biopharmaceutical company as sacituzumab govitecan is its lead product candidate. The CRL will in fact, delay its approval. The company’s portfolio includes antibody-drug conjugates (ADCs), designed to deliver a specific payload of a chemotherapeutic agent directly to the tumor while reducing overall toxicities, usually associated with conventional administration of these chemotherapeutic agents.
Notably, the candidate already enjoys a Breakthrough Therapy Designation in the United States for the treatment of patients with mTNBC, having received at least two prior therapies for metastatic disease.
Per the company, a potential nod will make acituzumab govitecan the first and the only ADC approved drug for addressing mTNBC.
Share price of Immunomedics has rallied 13.1% in the past 12 months against the industry’s decline of 20.6%.
Meanwhile, the company has collaborated with AstraZeneca (AZN - Free Report) and Clovis Oncology to evaluate sacituzumab govitecan in earlier lines of therapy for mTNBC, and advanced urothelial cancer (UC) in combination with checkpoint and PARP inhibitors, respectively.
However, competition is stiff in the breast cancer market with the presence of dominant players like Roche (RHHBY - Free Report) .
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Immunomedics Gets CRL From FDA for Breast Cancer Candidate
Immunomedics, Inc., suffered a setback when the company received a Complete Response Letter (CRL) from the FDA with regard to the Biologics License Application (BLA) for its lead candidate sacituzumab govitecan.
The BLA is seeking an accelerated approval of sacituzumab govitecan for treating patients with metastatic triple-negative breast cancer (mTNBC), who have received at least two prior therapies for metastatic disease.
The issues related to the CRL primarily focused on Chemistry, Manufacturing and Control matters and hence, the company is not required to generate any new clinical or preclinical data.
The company plans to work with the FDA to solve this issue. Last July, the FDA notified the company that the BLA has been accepted and the agency granted Priority Review with a target action date of Jan 18, 2019.
The news comes as a disappointment for this clinical-stage biopharmaceutical company as sacituzumab govitecan is its lead product candidate. The CRL will in fact, delay its approval. The company’s portfolio includes antibody-drug conjugates (ADCs), designed to deliver a specific payload of a chemotherapeutic agent directly to the tumor while reducing overall toxicities, usually associated with conventional administration of these chemotherapeutic agents.
Notably, the candidate already enjoys a Breakthrough Therapy Designation in the United States for the treatment of patients with mTNBC, having received at least two prior therapies for metastatic disease.
Per the company, a potential nod will make acituzumab govitecan the first and the only ADC approved drug for addressing mTNBC.
Share price of Immunomedics has rallied 13.1% in the past 12 months against the industry’s decline of 20.6%.
Meanwhile, the company has collaborated with AstraZeneca (AZN - Free Report) and Clovis Oncology to evaluate sacituzumab govitecan in earlier lines of therapy for mTNBC, and advanced urothelial cancer (UC) in combination with checkpoint and PARP inhibitors, respectively.
However, competition is stiff in the breast cancer market with the presence of dominant players like Roche (RHHBY - Free Report) .
Zacks Rank
Immunomedics carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>